Johnson Thomas G, Schelch Karin, Mehta Sunali, Burgess Andrew, Reid Glen
Asbestos Diseases Research Institute, Sydney, NSW, Australia.
Cell Division Laboratory, The ANZAC Research Institute, Sydney, NSW, Australia.
Front Cell Dev Biol. 2019 Oct 1;7:221. doi: 10.3389/fcell.2019.00221. eCollection 2019.
Lung cancers and malignant pleural mesothelioma (MPM) have some of the worst 5-year survival rates of all cancer types, primarily due to a lack of effective treatment options for most patients. Targeted therapies have shown some promise in thoracic cancers, although efficacy is limited only to patients harboring specific mutations or target expression. Although a number of actionable mutations have now been identified, a large population of thoracic cancer patients have no therapeutic options outside of first-line chemotherapy. It is therefore crucial to identify alternative targets that might lead to the development of new ways of treating patients diagnosed with these diseases. The multifunctional oncoprotein Y-box binding protein-1 (YB-1) could serve as one such target. Recent studies also link this protein to many inherent behaviors of thoracic cancer cells such as proliferation, invasion, metastasis and involvement in cancer stem-like cells. Here, we review the regulation of YB-1 at the transcriptional, translational, post-translational and sub-cellular levels in thoracic cancer and discuss its potential use as a biomarker and therapeutic target.
肺癌和恶性胸膜间皮瘤(MPM)在所有癌症类型中5年生存率极低,主要原因是大多数患者缺乏有效的治疗选择。靶向治疗在胸段癌症中已显示出一定前景,尽管疗效仅限于携带特定突变或有靶点表达的患者。虽然目前已鉴定出许多可作用的突变,但大量胸段癌症患者除一线化疗外别无治疗选择。因此,确定可能带来治疗这些疾病新方法的替代靶点至关重要。多功能癌蛋白Y盒结合蛋白1(YB-1)可能就是这样一个靶点。最近的研究还将该蛋白与胸段癌细胞的许多固有行为联系起来,如增殖、侵袭、转移以及参与癌症干细胞样细胞活动。在此,我们综述胸段癌症中YB-1在转录、翻译、翻译后和亚细胞水平的调控,并讨论其作为生物标志物和治疗靶点的潜在用途。